Clozapine versus "high-dose" olanzapine in refractory early-onset schizophrenia: An open-label extension study

Sanjiv Kumra, Harvey Kranzler, Ginny Gerbino-Rosen, Hana M. Kester, Courtney DeThomas, Kathyrn Cullen, James Regan, John M. Kane

Research output: Contribution to journalArticle

40 Scopus citations

Abstract

Objective: A recent 12-week controlled comparison demonstrated the superiority of clozapine to "high-dose" olanzapine in adolescents with treatment-refractory schizophrenia. In the present study, the authors conducted a 12-week, open-label, follow-up study to examine changes in lipid and glucose metabolism in youths maintained on clozapine and to determine whether patients who were previously randomized to high-dose olanzapine (up to 30 mg/day) responded to clozapine. Method: Thirty three (14 clozapine, 19 olanzapine) (85%) of 39 patients were available for the present 12-week, open-label extension study. Extended safety data using an intention-to-treat analysis from the 14 subjects treated with clozapine for a total of 24 weeks are presented. In addition, we report the clinical outcomes for 10 of 19 olanzapine-treated patients who were switched after 12 weeks to clozapine due to treatment nonresponse. Clinical response was defined as a decrease of 30% or more in total Brief Psychiatric Rating score from week 12 and a Clinical Global Impression-Improvement rating of 1 (very much improved) or 2 (much improved). Results: The incidence of hypertriglyceridemia (defined as fasting triglycerides >125 mg/dL) (10/14 = 71%) and the incidence of "prediabetes" (defined as fasting blood glucose ≥100) (4/14 = 29%) at week 24 in the clozapine-treated subjects were notable. Seven (70%) of 10 of young patients with schizophrenia who failed treatment with "high-dose" olanzapine were found to respond to a 12-week, open-label clozapine trial. Conclusions: Clinicians and caregivers need to be aware of potential metabolic adverse events of long-term clozapine treatment. Adolescents with a poor response to olanzapine may do better on clozapine.

Original languageEnglish (US)
Pages (from-to)307-316
Number of pages10
JournalJournal of child and adolescent psychopharmacology
Volume18
Issue number4
DOIs
StatePublished - Aug 1 2008

Fingerprint Dive into the research topics of 'Clozapine versus "high-dose" olanzapine in refractory early-onset schizophrenia: An open-label extension study'. Together they form a unique fingerprint.

  • Cite this